CJC-1295 (with DAC)
A synthetic analogue of growth-hormone-releasing hormone, linked to a chemical group that binds albumin to prolong its action. Studied in early clinical trials in the 2000s.
Level of evidence
Clinical trials — controlled human studiesWhat it is
CJC-1295 is a modified version of the first 29 amino acids of growth-hormone-releasing hormone (GHRH). The “DAC” (Drug Affinity Complex) is a reactive group that attaches the peptide to albumin in the blood, which lengthens its half-life.
State of the research
Small clinical studies in healthy adults were published in 2006. Development did not lead to an approved medicine.
Sources
Last reviewed: October 2026
Summaries of published scientific literature, for information and laboratory research only. They do not describe uses of our products, are not medical advice and do not imply that any compound is safe or effective in humans. Our products are not for human or animal consumption.